Get the Stockscreener App
5.13
0.00%
0.00
After Hours:
5.09
-0.04
-0.78%
Harvard Bioscience Inc stock is traded at $5.13, with a volume of 16,745.
It is up +0.00% in the last 24 hours and down -15.02% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
See More
Previous Close:
$5.13
Open:
$5.19
24h Volume:
16,745
Relative Volume:
0.36
Market Cap:
$22.94M
Revenue:
$86.55M
Net Income/Loss:
$-56.70M
P/E Ratio:
-1.9951
EPS:
-2.5713
Net Cash Flow:
$4.87M
1W Performance:
+5.12%
1M Performance:
-15.02%
6M Performance:
+16.80%
1Y Performance:
-13.36%
1-Day Range:
$5.02
$5.19
1-Week Range:
$4.71
$5.75
52-Week Range:
$2.813
$9.458
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
5.13 | 22.94M | 86.55M | -56.70M | 4.87M | -2.5713 |
ISRG
Intuitive Surgical Inc
|
469.98 | 167.61B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 44.35B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.19B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.11B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 33.24B | 5.40B | 1.49B | 1.78B | 10.12 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
EBIT of Harvard Bioscience, Inc. – MUN:HBI0 - TradingView
HARVARD BIOSCIENCE (NASDAQ: HBIO) CEO receives 75,000-share stock grant - Stock Titan
William Snider Secures Board Seat at Harvard Bioscience with 15.97% Stake - TradingView
BroadOak reports 16% Harvard Bioscience (HBIO) stake tied to loans and warrants - Stock Titan
Harvard Bioscience stock faces scrutiny amid Q4 earnings anticipation and life sciences sector volat - AD HOC NEWS
Taxes of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Harvard Bioscience Outlines Post-Refi Strategy, Organoid Growth Focus - National Today
Total equity of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LS:A423J5 - TradingView
Free cash flow per share of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView
Equity in earnings of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Cash per share of Harvard Bioscience, Inc. – GETTEX:HBI0 - TradingView
Harvard Bioscience, Inc. Cash Flow – GETTEX:HBI0 - TradingView
Net income of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Price to earnings ratio of Harvard Bioscience, Inc. – GETTEX:HBI0 - TradingView
Net debt of Harvard Bioscience, Inc. – LSX:A423J5 - TradingView
Return on assets % of Harvard Bioscience, Inc. – LSX:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LSX:A423J5 - TradingView
Insider Buying: Stephen Denelsky Acquires 10,000 Shares of Harva - GuruFocus
Harvard Bioscience (HBIO) director Denelsky buys $48,700 in shares By Investing.com - Investing.com India
Harvard Bioscience (HBIO) director Denelsky buys $48,700 in shares - Investing.com
Harvard Bioscience (NASDAQ:HBIO) Director Stephen Denelsky Purchases 10,000 Shares - MarketBeat
Harvard Bioscience (HBIO) director buys 10,000 shares in open market - Stock Titan
Harvard Bioscience director Snider buys $103,603 in HBIO stock By Investing.com - Investing.com India
Harvard Bioscience (NASDAQ:HBIO) Director William Snider Acquires 12,525 Shares - MarketBeat
Harvard Bioscience director Snider buys $103,603 in HBIO stock - Investing.com
Harvard Bioscience (HBIO) director buys 21,000 shares on open market - Stock Titan
HBIO Stock Price, Quote & Chart | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience CEO Duke buys $25k in shares By Investing.com - Investing.com Australia
Layoff Watch: What are analysts price targets for Harvard Bioscience IncTrade Analysis Report & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Insider Buying: John Duke Acquires 5,000 Shares of Harvard Biosc - GuruFocus
Harvard Bioscience CEO Duke buys $25k in shares - Investing.com
Harvard Bioscience (HBIO) CEO adds shares and holds major RSU awards - Stock Titan
Harvard Bioscience at KeyBanc Forum: Strategic Growth and Market Focus By Investing.com - Investing.com Canada
Harvard Bioscience outlines 2026 guidance with 2%–4% revenue growth and high-margin focus following structural improvements - MSN
Harvard Bioscience 2026 Investor Overview: Translational Science Tools, Growth Strategy, and Financial Outlook - Minichart
Harvard Bioscience (HBIO) Earnings Transcript - AOL.com
Harvard Bioscience Highlights CFO Appointment and Strategic Repositioning - TipRanks
Market Trends: Whats next for Harvard Bioscience Inc stockRisk Management & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Harvard Bioscience provides investor presentation; FY25 results, FY26 guidance and strategic actions - TradingView
Harvard Bioscience (NASDAQ: HBIO) posts FY25 metrics and guides modest 2026 growth - Stock Titan
HBIO: Benchmark Raises Price Target to $6.00, Maintains Speculat - GuruFocus
Benchmark raises Harvard Bioscience stock price target to $6 on reverse split - Investing.com Australia
Benchmark raises Harvard Bioscience stock price target to $6 on reverse split By Investing.com - Investing.com India
How The Harvard Bioscience (HBIO) Investment Narrative Is Resetting After Lower 2026 Expectations - Yahoo Finance
Benchmark cuts Harvard Bioscience stock price target on NIH concerns - Investing.com Nigeria
HBIO: Analyst Bruce D. Jackson Maintains Rating but Lowers Price Target | HBIO Stock News - GuruFocus
Benchmark cuts Harvard Bioscience stock price target on NIH concerns By Investing.com - Investing.com South Africa
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2025 Earnings Call Transcript - Insider Monkey
Harvard Bioscience 2025 10‑K: Revenue $86.6M, Gross Profit $49.91M - TradingView
Harvard Bioscience Q4 2025 slides: margins hit 7-quarter high By Investing.com - Investing.com Canada
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):